Evaluation of the Safety, Pharmacokinetics and Efficacy of Three Doses of YN968D1 in Subjects With Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Bukwang Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Results assessing preliminary efficacy and safety of apatinib in advanced solid tumors (n=30) presented at the 41st European Society for Medical Oncology Congress.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History